Cardiovascular and Metabolic Disease Center
Mitochondrial Research Affinity Collaboration-Laboratories & Engineering

Home > 0

Understanding Cell Death May Bring New Life To Kidney Treatment

  • 작성자한진
  • 작성일2006-04-21 20:05:25
  • 조회수2190
  • 첨부파일첨부파일
Finding how two proteins conspire to get kidney cells to self-destruct when oxygen supplies are low may one day improve dismal mortality rates for ischemic renal failure, researchers say. Dehydration, low blood pressure, septic shock, trauma or removing a kidney for transplantation can temporarily halt or reduce blood and oxygen supplies, says Dr. Zheng Dong, cell biologist at the Medical College of Georgia. Ischemia leads to cell suicide or apoptosis, particularly in the energy-consuming tubular cells of the kidneys, he says. Fifty percent mortality rates from resulting ischemic renal failure haven’t changed in nearly as many years, Dr. Dong says. Tubular cells – which have the daunting daily task of reabsorbing nearly 50 gallons of usuable fluid volume, including salt and glucose the kidneys filter from the blood every 24 hours – are particularly vulnerable to apoptosis and injury, Dr. Dong says. “They are highly energy-dependent,” he says. “That is why when you shut off the blood supply, these cells are quickly, irreversibly damaged and they die.” Tubular cell injury and death is why kidneys are so vulnerable, for example in critically ill patients. It’s in this oxygen-deprived environment that two proteins, Bid and Bax – each a known killer in its own right – are activated and may partner to induce cell death. The killing proteins are pervasive, particularly in the kidneys, says Dr. Dong, who recently received a $1 million grant from the National Institute of Diabetes & Digestive & Kidney Diseases, to better understand their role in cell death during ischemic renal failure. In both cell culture and animal models of ischemic renal injury, Dr. Dong and his colleagues have found Bid is cleaved or cut, releasing active fragments. Although he still doesn’t know what cuts Bid, that act enables the protein to move from its usual place in the outer region of the cell to inside its powerhouses or mitochondria. Cleaving results in what Dr. Dong calls truncated Bid or “tBid,” which may interact with Bax and produce a conformational change. “Now Bax can move,” says Dr. Dong, and it also heads straight for the mitochondria, which normally feed and oxygenate cells. Once inside, Bax bits re-collect, forming a complex capable of making a hole in the mitochondria and enabling molecules, such as cytochrome C, a major enabler of cell respiration, to escape. “This process as we have shown probably is mediated by Bax, and now we have found that Bid can be a critical trigger of Bax,” Dr. Dong says. A Bid knockout mouse model, developed at the University of Pittsburgh, helps illustrate the synergism. Without Bid, there is less apoptosis while kidney function and survival rates significantly improve. Also, interestingly, without Bid, cell regeneration that helps the kidney recover from ischemia is slower, he notes. The kidney normally has some capacity to regenerate, with surviving cells quickly stretching to cover holes left by dead cells and later dividing to form more cells for tissue repair. “Within a couple of hours, neighboring cells will stretch to cover the wound, to take up the work of the dying cells,” Dr. Dong says. Unfortunately, while some kidney cells are working hard to make up the loss, Bid and Bax continue to trigger apoptosis and eventually the kidney fails, he says. One goal is finding the protease that cleaves Bid – he doesn’t think it’s Bax – and following the ensuing cascade to better understand the process so it can be manipulated to stop needless cell death or, in the case of cancer, enhance self-destruction. In related research, Dr. Dong’s lab is studying kidney damage caused by the common chemotherapeutic agent, Cisplatin, used for testicular, ovarian and small cell lung cancer, head and neck tumors and more. Renal function is closely monitored while on therapy because of the drug’s known side effects in the kidney. “We want to see how the drug can kill kidney cells and if we can find a protective mechanism to prevent kidney cell death without stopping cancer cell death,” says Dr. Dong. He thinks the answer may be in the differences between healthy and cancerous cells.
Total404 [ page1/27 ]
No. 제목 작성자 작성일 조회수
404 인제대, 과기정통부 ‘2023년도 기초연구실 지원사업’ 선정 2023.09.13 관리자 (web_admin) 2023.09.13 7
403 인제대 교수팀 '돌연사 주범 심부전 원인 규명' 2023.09.13 관리자 (web_admin) 2023.09.13 5
402 2022학년도 인제학술상 수상자 선정 결과 2023.01.05 관리자 2023.01.05 57
401 안전관리 우수연구실 인증 취득 2023.01.05 관리자 2023.01.05 40
400 한진교수 화의자의학상 수상 2023.01.05 관리자 2023.01.05 57
399 이온통로 학회 -Amy 포스터상 수상 2019.01.15 김형규 2019.01.15 2,587
398 센터 겸임교수 조성우 교수 - 한빛사 -JACC Vascular Imaging 2018.12.08 김형규 2018.12.08 2,791
397 2017 IMPACT Symposium 개최 첨부파일 2017.10.31 김보현 2017.10.31 2,588
396 경암바이오유스 2017 첨부파일 2017.08.11 김보현 2017.08.11 2,871
395 KORUS 2017 첨부파일 2017.06.21 김보현 2017.06.21 2,986
394 IMPACT 2016 심포지엄 개최 안내 첨부파일 2016.04.18 관리자 2016.04.18 4,000
393 IMPACT 2015 심포지엄 개최 안내 첨부파일 2015.04.20 서대윤 2015.04.20 2,869
392 2015 중점연구소 성과 전시회 첨부파일 2015.03.31 김형규 2015.03.31 2,462
391 Best Miso Award - 한진 2014.11.04 이정훈 2014.11.04 2,072
390 신진생리학자상 - 김형규 2014.10.29 이정훈 2014.10.29 1,816
처음이전1 2 3 4 5 6 7 8 9 10 다음 마지막